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Since the early 1950s when sexually transmitted infections (STIs) were first proposed as 
a possible risk factor for prostate cancer, numerous epidemiologic studies have been conducted. 
Initially, these studies were primarily small case-control studies with retrospective, self-reported 
assessment of a narrow range of STIs, typically either any STIs, or gonorrhea and syphilis. 
However, as new STIs have been discovered/recognized, new and better tests to detect histories 
of STIs have been developed, and new resources for prostate cancer research have been created, 
epidemiologic studies have expanded to include a wider range of STIs, and have moved towards 
more rigorous, prospective study designs and serologic assessment of STI histories. The results 
of these studies are reviewed and discussed, as well as possible new avenues of research, such as 




EARLY HYPOTHESES FOR SEXUALLY TRANSMITTED INFECTIONS AND 
PROSTATE CANCER 
Early hypotheses related to a sexually transmitted etiology of prostate cancer were 
initially motivated by contemporary, epidemiologic patterns of prostate cancer occurrence. In the 
early 1950s, Ravich and Ravich [1, 2] noted a higher prostate cancer prevalence among mainly 
uncircumcised non-Jewish than circumcised Jewish men, similar to patterns for penile cancer 
and cervical cancer among female partners of these men, leading them to propose that observed 
patterns might be explained by sexual transmission of a virus or other carcinogenic agent 
contained within the smegma of uncircumcised males. Subsequent investigators [3-5] further 
proposed additional hypotheses related to infection, sexual behavior, and sexual frustration to 
explain other contemporary patterns of prostate cancer occurrence by marital, paternal, and racial 
status. Together, these observations and hypotheses led to a series of investigations beginning in 
the early 1970s to examine possible associations between STIs and sexual behavior in relation to 
prostate cancer.    
Selection of STIs 
STI markers:  
Most early investigations of STIs and prostate cancer assessed either a history of any 
STIs or individual histories of gonorrhea and syphilis as markers or possibly vectors of the 
potentially causative STI or sexual behavior [6-9]. These STIs were likely selected because they 
were the most common, well-known, and symptomatic STIs at the time, making them also more 
readily assessed by self-report, medical record abstraction, or registry query.  
Prostate inflammation:  
Other early studies focused specifically on gonorrhea because it frequently led to 
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secondary gonococcal prostatitis in the pre- and early-antibiotic era, and because prostate 
inflammation had previously been hypothesized as a cause of atrophy and subsequent prostate 
cancer ([9-11] and references therein). This inflammation-atrophy-prostate cancer hypothesis has 
since gained further support with the observation of morphological and epigenetic transitions 
between areas of inflammation-associated, highly proliferative, atrophic prostatic epithelium, 
which have been termed proliferative inflammatory atrophy (PIA) lesions, and areas of high-
grade prostatic intraepithelial neoplasia (PIN) and adenocarcinoma. According to this developing 
hypothesis, PIA lesions are believed to form as a result of prostate epithelial cell damage and 
destruction caused by secretion of oxygen- and nitrogen-based reactive molecules from 
inflammatory cells, such as neutrophils and macrophages. Over time, small subsets of cells 
within these regenerative lesions are believed to acquire somatic genomic alterations, such as 
hypermethylation of the oxygen radical detoxifying glutathione S-transferase P1 gene, making 
them more susceptible to genomic damage. This increased susceptibility to genomic damage has 
then been postulated to lead to the development of PIN lesions or cancer in the setting of 
continued or repeated inflammation and cell injury/death [12].    
In addition to proposing gonorrhea as a possible inflammatory cause of prostate cancer, 
Wynder and colleagues [10] further proposed that “frequent venereal infections or untreated 
chronic venereal infection” might be of interest because these infections were also believed to 
contribute to prostatitis; in this case, non-gonococcal prostatitis. Indeed, in the pre- and early- 
antibiotic era, prostatitis due to organisms other than Neisseria gonorrhoeae, the causative agent 
of gonorrhea, was frequently observed in both men with gonococcal urethritis who may have 
acquired additional sexually transmitted organisms at the time of infection with N. gonorrhoeae, 
and men with non-gonococcal urethritis [13]. However, no early studies, to our knowledge, 
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investigated any of these other common causes of STI-specific prostatitis, possibly because 
some, such as Trichomonas vaginalis, were generally less well recognized and less frequently 
investigated or diagnosed in men, making them difficult to assess by self-report, while others, 
such as Chlamydia trachomatis, had not yet been discovered or recognized as sexually 
transmitted pathogens. Therefore, these pathogens would not be investigated in relation to 
prostate cancer until several decades later. 
Carcinogenic STI therapy:  
Rather than focusing on prostate inflammation, Lees and colleagues [14] investigated 
syphilis, a very rare cause of granulomatous prostatitis [15], because of the potentially 
carcinogenic effects of pre-antibiotic era, parenteral, arsenical therapy for syphilis. 
Viral transformation:  
Finally, other groups investigated herpesviruses, such as herpes simplex virus type 2 
(HSV-2), cytomegalovirus (CMV) and Epstein-Barr virus (EBV), because they: 1) had been 
demonstrated to have transforming properties; 2) had been observed in malignant prostate 
tissue/cell lines; and 3) were believed to be involved in the development of other cancers, such as 
cervical cancer and Burkitt’s lymphoma [8, 16-20]. Primitive serologic tests were available for 
these viruses as early as the 1970s, making it possible to assess histories of these infections by 
serology rather than or in addition to self-report or medical record abstraction.  
Since these early hypotheses were first proposed, several new STIs have been discovered 
or recognized, and new and better methods to investigate STI histories have been developed; 
however, the rationale behind investigation of these STIs has remained largely the same over the 
years, primarily focused on prostate inflammation and viral transformation.  
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RESULTS FOR EARLY STUDIES OF STIS AND PROSTATE CANCER 
STIs assessed by self-report, medical record abstraction, or registry query: 
Considering early studies of STIs and prostate cancer conducted among men more likely 
to have been infected in the pre-antibiotic era, several observed suggestive positive associations 
for histories of any STIs [6-8, 21] and gonorrhea [9, 11, 17], while others observed null or 
suggestive inverse associations for these STIs [10, 14, 22-25] (Table 1). Fewer studies 
investigated a history of syphilis in relation to prostate cancer [14, 17, 23], one of which 
observed a positive association [14], and the other two observed generally null, unstable results 
[17, 23]. With respect to other STIs or symptoms of STIs, one study observed a suggestive 
positive association for self-reported history of urethral discharge (possibly indicative of 
gonorrhea or another exudative STI) [26], while another observed unstable positive and null 
associations for “recurrent genital sores” (possibly indicative of genital herpes) and pediculus 
pubis (pubic lice), respectively [17]. Finally, in studies with sufficient numbers of exposed 
participants, suggestive positive associations were observed for histories of STIs or STI 
symptoms among participants’ female partners, including histories of any STIs [8] and “genital 
infection” [26], with prostate cancer among participants. Most other investigations of 
participants’ female partners had too few exposed participants to interpret their findings [23-28]. 
Taken together, these findings suggested that one or more of the more commonly reported STIs, 
such as gonorrhea, or another unmeasured or unknown correlated STI, might be associated with 
risk of prostate cancer.  
Interpretation of study findings: 
Information bias: 
One concern for interpretation of early study findings is the possibility that many may 
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have been influenced by biases, such as recall and interviewer biases, because most early studies 
were case-control in design with retrospective, self-reported assessment of STI histories. This 
type of study design and exposure assessment allows for the possibility that participants’ 
knowledge of their prostate cancer status or awareness of their physicians’ or interviewers’ 
knowledge of their status may have influenced their responses to study questions, particularly 
sensitive questions, such as those related to STI histories. This knowledge may have led prostate 
cancer cases to reply more truthfully to questions about STI histories than controls, thereby 
possibly leading to a higher reported lifetime prevalence of STIs among cases than controls. In 
some early studies of STIs and prostate cancer, interviewers were also likely aware of both 
participants’ cancer status and study hypotheses, which may have led them to question prostate 
cancer cases more thoroughly for information on STI histories than controls, thereby possibly 
further contributing to a higher reported lifetime prevalence of STIs among cases than controls. 
Confounding: 
Another factor that may have led to false positive associations is the possibility of 
confounding by hormone levels, as these may have contributed to both increased sexual activity 
and thus increased likelihood of acquiring an STI, as well as increased risk of prostate cancer. To 
our knowledge, no early studies were able to address this possible concern, nor did any adjust for 
correlates of hormone-associated libido.  
Etiologic relevance of the STI exposure: 
Although early studies may have been susceptible to information biases and confounding, 
and thus to observing false positive associations, they may have also been more likely to capture 
STI histories of possibly greater relevance for prostate carcinogenesis than studies that have 
since been conducted because early participants were more likely to have passed through 
8 
 
adolescence and early adulthood (when men typically acquire STIs [29]) before antibiotics had 
been developed. During this pre-antibiotic period, 1) some STIs, such as syphilis [30], were more 
prevalent and more evenly spread throughout the population (i.e., less restricted to specific 
populations), thus increasing the likelihood of infection and repeat infections; 2) several STIs, 
such as gonorrhea and syphilis, were more likely to persist because of ineffective treatment; and 
3) many STIs were more likely to result in sequela, such as prostatitis or prostatic abscess in the 
case of gonorrhea [31]. Therefore, the likelihood of single or multiple episodes of assessed STIs 
and co-infections, and their duration and probability of sequela, were likely greater among 
participants in earlier that later studies. We have previously hypothesized that these 
characteristics may be important for prostate carcinogenesis because each may increase the 
chance and/or duration of either asymptomatic or symptomatic prostate involvement. Multiple 
episodes of STIs may be more relevant for carcinogenesis than single episodes because of 
increased cumulative probability of prostate involvement with each STI episode and increased 
cumulative probability of inflammatory immune injury with each episode that involves the 
prostate. Infections of longer duration may also be more relevant for carcinogenesis than shorter 
infections because of the greater length of time afforded to infectious agents to ascend to the 
prostate and the greater potential duration of prostate involvement. Finally, sequela, such as 
clinical prostatitis, are relevant to prostate carcinogenesis because they directly represent prostate 
involvement and possible inflammatory immune damage to prostate epithelium [32]. 
Etiologic relevance of the prostate cancer outcome:  
A final consideration for interpretation of early study findings for STIs and prostate 
cancer is the spectrum of prostate cancer presentation in these studies. All early studies were 
conducted before the introduction of prostate specific antigen (PSA) testing for early detection of 
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prostate cancer; therefore, these studies may have included a higher proportion of clinically 
manifest prostate cancer, such as cancer that was detectable by digital rectal examination or had 
progressed to metastases, than later studies. These clinically manifest or life-threatening prostate 
tumors may potentially have differing etiology than tumors that never progress to clinically-
manifest disease [33]. Therefore, considering this issue together with all aforementioned issues, 
it is difficult to determine the relative contributions of possible biases in study design, 
confounding, greater STI exposure, and later prostate cancer presentation to observed findings 
from early studies of predominantly self-reported STIs and prostate cancer. 
STIs assessed by serology or other laboratory methods: 
As mentioned previously, primitive serologic assays were available for several 
herpesviruses as early as the 1970s and 80s, allowing for seroepidemiologic investigations of 
HSV-2, CMV and EBV infection in relation to prostate cancer. Results from these early studies 
were generally mixed; while some observed suggestive positive associations for HSV-2 [17] and 
CMV [19] seropositivity, others observed null or suggestive inverse associations for these 
viruses and EBV [8, 16] (Table 1). A few additional small studies also investigated herpesvirus 
nucleic acids and antigens in prostate tissue with generally unstable results [17, 18, 20]. 
Interpretation of study findings: 
Non-differential exposure misclassification: 
Although serologic studies are not susceptible to recall and interviewer biases, exposure 
misclassification may still have been introduced into early studies of herpesviruses and prostate 
cancer, especially studies of HSV-2, because of the extensive cross-reactivity between HSV-2 
antigens and those expressed by the more common HSV-1 [34]. This cross-reactivity may have 
led to a considerable number of individual false positive test results and falsely elevated 
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seroprevalences, as evidenced by a comparison of HSV-2 seroprevalences from older studies 
(51-66% among controls [16, 17]) and more recent studies (24.3% among men and women 60-69 
years of age) [35]. Although this cross-reactivity is unlikely to have been differential by case-
control status, its considerable extent makes interpretation of study findings difficult.    
RESULTS FOR LATER STUDIES OF STIS AND PROSTATE CANCER 
STIs assessed by self-report, medical record abstraction, or registry query: 
Case-control studies: 
Since the first early studies of STIs and prostate cancer were conducted, several 
additional case-control studies have investigated possible associations between a history of any 
STIs and individual histories of gonorrhea, syphilis, and other STIs typically assessed by self-
report in relation to prostate cancer. Many, but not all [36, 37], of these later studies observed 
suggestive positive associations for histories of any STIs [38, 39] and gonorrhea [40-44] where 
sufficient numbers of exposed participants existed (Table 2). A few additional studies with much 
smaller numbers of exposed participants observed generally unstable estimates [45-48]. For 
syphilis, only one case-control study had sufficient numbers of exposed participants to evaluate 
its association with prostate cancer; this study observed a positive association for both self-
reported and serologically detected history of syphilis [41]. Although unstable, estimates from 
the remaining case-control studies of syphilis were also generally supportive of a positive 
association when considered together [37, 42-45, 48]. Finally, generally unstable results or no 
reported exposure were observed in other studies of genital herpes [37, 42, 43, 45, 49], genital 
warts [42, 48, 50], urethritis [42], chancroid [37], “other” STIs [36, 37, 43, 45], and cervical 
cancer among participants’ female partners [43, 47]. Thus, similar to earlier case-control studies, 
later case-control studies generally observed suggestive positive associations for a history of any 
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STIs and individual histories of gonorrhea and possibly syphilis, where sufficient numbers of 
exposed participants existed.      
Interpretation of study findings: 
Etiologic relevance of the STI exposure and prostate cancer outcome: 
As compared to participants in earlier case-control studies, those in later studies were less 
likely to have passed through adolescence and early adulthood before antibiotics had been 
discovered and thus may have been less likely to have ever had an STI, to have had multiple 
episodes of STIs or co-infections, or to have had a lengthy duration of infection or sequela than 
participants in earlier studies. Indeed, with respect to ever having been infected, self-reported 
lifetime prevalences of STIs have generally decreased over time in case-control studies, 
particularly those composed predominantly of Caucasian men. Participants in later studies also 
typically presented at an earlier stage of prostate cancer than those in earlier studies, which may 
have possibly shifted the composition of prostate tumors towards those that may have never 
progressed to clinically manifest or life-threatening disease. Both of these factors – lesser 
likelihood of extensive STI exposure and earlier prostate cancer presentation – might be 
expected to decrease the likelihood of observing true positive associations between STIs and 
prostate cancer. 
Confounding: 
Similar to findings from earlier case-control studies, those from later studies may also 
potentially have been influenced by confounding by hormone-associated libido, thereby possibly 
leading to false positive associations. However, a few results from later studies suggest this 
possibility may be less of a concern. In both positive studies that adjusted for correlates of libido 
– sexual activity with prostitutes, number of sexual partners, and frequency of sexual intercourse 
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– similar positive findings were observed as in unadjusted/lesser-adjusted analyses [39, 41], 
suggesting that, at least in these two studies, positive results were likely not due to confounding 
by hormone-associated libido.     
Information bias: 
Finally, as compared to earlier studies, later case-control studies may have been less 
susceptible to interviewer bias because many assessed STI histories by self-administered 
questionnaires and because use of interviewer blinding has likely increased over time. Therefore, 
later case-control studies should have been less likely to observe false positive associations due 
to interviewer bias than earlier studies. However, one lingering, possible methodologic concern 
that may still potentially have contributed to false positive associations in later studies is recall 
bias, as all later studies assessed STI histories after prostate cancer diagnosis, and as the STI-
prostate cancer hypothesis has now been circulating in the medical and lay community for 
several decades. 
Prospective studies: 
To our knowledge, only a few studies have prospectively investigated associations 
between gonorrhea, syphilis and prostate cancer to avoid concerns of recall bias. The first two of 
these studies were conducted in the 1990s, one of which observed a relatively unstable estimate, 
possibly supportive of a positive association, between a history of gonorrhea and risk of prostate 
cancer in a nested case-control study [51], while the second observed a significant inverse 
association between a history of syphilis and prostate cancer risk in a retrospective cohort study 
that compared prostate cancer incidence among cases of syphilis reported to the New York State 
Health Department to incidence in the general New York State population [52] (Table 3). 
However, this study has been criticized for possible under-ascertainment of prostate cancer cases 
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that developed outside of the study catchment area in the syphilis cohort [53]. Indeed, inverse 
associations were also observed for colon, rectum, bladder and lung cancer [52], the latter two of 
which might be expected to be positively associated with syphilis due to confounding by 
smoking, as smoking and STI histories tend to be correlated [54]. Until very recently, these were 
the only two prospective studies in the literature. However, more prospective studies are now 
beginning to be conducted. In 2006, we published the results of our prospective cohort 
investigation in the Health Professionals Follow-up Study (HPFS), in which we observed no 
association for a history of gonorrhea and an unstable, null association for a history of syphilis 
and risk of prostate cancer [55]. Based on participants’ lower reported lifetime prevalence of 
STIs, which we have previously hypothesized also reflects a lower likelihood of repeat and co-
infections [32], as well as their education, socio-economic status, and race/ethnicity, we 
postulated that histories of gonorrhea and syphilis in this cohort likely reflected only one or two 
episodes of treated infection with a low likelihood of co-infections. Therefore, our findings 
suggested that low exposure to gonorrhea and syphilis does not increase risk of prostate cancer 
[55]. These findings were supported by subsequent results in the Prostate, Lung, Colorectal and 
Ovarian (PLCO) Cancer Screening Trial, in which the authors observed no association for a 
history of gonorrhea, and an unstable, possibly inverse association for a history of syphilis 
among Caucasian participants, who had similarly low reported lifetime prevalences of infection 
as HPFS participants. Null or generally unstable results were also observed, however, among 
African-American participants in the PLCO Cancer Screening Trial [56] and among Caucasian 
and African-American participants in the subsequent California Men’s Health Study [57], all of 
whom had considerably higher reported lifetime prevalences of gonorrhea and syphilis than 
HPFS or Caucasian PLCO participants. Therefore, these findings suggest that any exposure to 
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gonorrhea or syphilis, even more extensive exposure, at least as experienced in the U.S. in the 
current antibiotic era, does not increase risk of prostate cancer.  
It is possible, however, that other types of infection may increase risk of prostate cancer – 
for instance, those more similar to infections experienced in the pre-antibiotic era. This 
possibility is suggested by findings from the recent California Men’s Health Study. While no 
association was observed for a history of gonorrhea overall in this study population or among 
U.S. born Latino men (relative risk (RR)=1.02, 95% confidence interval (CI): 0.63-1.67), a 
suggestive positive association was observed among foreign-born Latino men (RR=1.95, 95% 
CI: 1.20-3.16), whom the authors hypothesized may have been more likely to have been infected 
outside of the U.S., and thus not to have received any or timely treatment. This hypothesized lack 
or delay in treatment may have then led to a longer duration of infection, and a possibly greater 
likelihood of prostate involvement. A similar, albeit less stable, positive association was also 
observed for syphilis among Asian-American men, another more recent immigrant group to the 
U.S. [57]. Therefore, although these sub-group findings may have observed by chance, they 
leave open the possibility of associations between certain types of STI histories (e.g., untreated 
STIs, and those of longer duration) and prostate cancer. Thus, additional prospective studies with 
a greater variety of STI exposures may be warranted to elucidate the possible roles of gonorrhea 
and syphilis in prostate carcinogenesis.  
STIs assessed by serology and other laboratory methods 
Since the original hypothesis on STIs and prostate cancer was first proposed, several new 
STIs have been discovered or recognized as STIs (e.g., infections by oncogenic HPV types, 
human herpesvirus type 8 (HHV-8) and C. trachomatis), and new or considerably better tests to 
detect histories of other known STIs have been developed (e.g., HSV-2 and T. vaginalis 
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infections). New resources for prostate cancer research have also been created (e.g., cohort 
studies with blood collection), allowing for prospective investigations of STIs and prostate 
cancer risk, and serologic detection of STI histories, both of which serve to reduce concerns of 
recall bias. In general, histories of these newly discovered/recognized STIs are also better 
assessed by serology than by self-report because many of these STIs tend to be asymptomatic in 
men, and infrequently diagnosed in symptomatic men. Although serology may not capture all 
past infections in men, we have previously hypothesized that it may be better at detecting 
infections of possibly greater relevance for prostate carcinogenesis, such as repeat infections, 
infections of longer duration that might be more likely to ascend to the prostate, and those with 
complications, such as prostatitis, because detectable or higher antibody titers have been 
observed among individuals with HPV or HHV-8 infections of longer duration; individuals with 
Kaposi’s sarcoma, a complication of HHV-8 infection; and women with chlamydial salpingitis, a 
complication of C. trachomatis infection (chlamydia), than among individuals with 
uncomplicated or transient infections, such as those limited to the lower genitourinary tract [[58] 
and references therein]. However, despite its possibly greater sensitivity for etiologically relevant 
histories of infection, serology may also falsely identify some men who have never been infected 
as seropositive, leading to non-differential misclassification of exposure and a possible bias of 
the results towards the null. 
Human papillomavirus infection 
Of the aforementioned STIs, the first to be extensively investigated in relation to prostate 
cancer was HPV infection, particularly types 16 and 18, because of their newly discovered causal 
associations with several anogenital cancers, including cervical, penile, and anal carcinomas 
[59]. This discovery led to a series of tissue-based and seroepidemiologic investigations of HPV 
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infection and prostate cancer beginning in the early 1990s. While the first of these studies 
observed suggestive positive findings [60-64], spurring additional research into this field, most 
subsequent studies have observed generally null results [[65] and references therein, [56, 58, 66-
74]]. (Findings from most previous tissue-based studies have been expertly summarized in 
Strickler and Goedert’s review article [65]; findings from seroepidemiologic studies are 
summarized in Table 4). Initially, investigators proposed that discrepancies between earlier and 
later seroepidemiologic findings might be due to differences in the timing of specimen collection 
relative to prostate cancer diagnosis, as earlier positive studies collected serum specimens 
decades before prostate cancer diagnosis, whereas later null studies generally collected 
specimens a few years before or at the time of diagnosis [65]. Therefore, antibody titers could 
have possibly waned since an earlier, causative “hit and run” HPV infection or related sexual 
factor [65], or during the process of invasive prostate cancer development [66]. However, as null 
findings have since been observed in more recent seroepidemiologic studies with early specimen 
collection [70, 73], and as minimal/no evidence of high-risk HPV DNA has been observed in 
most recent investigations of prostate cancer tissue [68, 69, 72, 75-79], these explanations seem 
less likely. Instead, it appears more likely that HPV infection does not influence prostate cancer 
risk, at least by biologic mechanisms proposed to date. Therefore, unless new biologic 
mechanisms are proposed, or radically new laboratory and/or epidemiologic methods are 
developed, further similar investigations are unlikely to yield additional insight.   
Human herpesvirus type 8 infection 
Although not as extensively studied as HPV infection, HHV-8 infection was also 
investigated in relation to prostate cancer because of its recently discovered causal relation with 
other cancers, namely Kaposi’s sarcoma and primary effusion lymphoma [80]. Initially, studies 
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of HHV-8 infection and prostate cancer observed null associations [81, 82] or detected no 
evidence of HHV-8 infection when comparing cancerous to benign prostate tissue [83, 84] 
(Table 5). However, in 2004, Hoffman and colleagues [85] observed positive findings between 
HHV-8 seropositivity and prostate cancer in a series of case-control comparisons, most notably 
one conducted among men of African descent from Tobago, motivating several additional 
seroepidemiologic investigations. None of these subsequent investigations have, however, 
observed positive findings. Instead, most have observed findings more consistent with a null or 
even an inverse association [56, 58, 86, 87], leading the authors of the first positive study to 
propose that discrepancies between these null/inverse findings and their positive findings might 
be due to chance or possibly to an unknown environmental or genetic difference between 
Tobagan men and men from other study countries, as their positive association has reportedly 
remained significant after analysis of additional specimens from Tobago [87]. Therefore, more 
targeted investigations may be necessary to disentangle these two possibilities, and to explore a 
possible inverse association between HHV-8 infection and prostate cancer. 
HSV-2, CMV and EBV infections 
Although other herpesviruses, such as HSV-2, CMV, and EBV, were first investigated in 
relation to prostate cancer as early as the 1970s, only a handful of studies have been conducted 
on these viruses to date, most of which were conducted in the last few years after the 
introduction of new, considerably less cross-reactive serologic assays for HSV-2. However, 
despite use of these new, improved assays, most later studies of HSV-2 [56, 73, 86, 88], CMV 
[56, 88] and EBV seropositivity [88] have observed null or generally unstable associations with 
prostate cancer (Table 5). One exception to this statement is the recently observed positive 
association between HSV-2 seropositivity and prostate cancer risk in a U.S. military study using 
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serum specimens collected a mean of 94 months before diagnosis, but not using specimens 
collected a mean of 10 months before diagnosis [73]. However, as no association was observed 
in the only other study with early specimen collection [86], these findings may have been 
observed by chance. Finally, in a later tissue-based study, no association was observed for EBV 
DNA positivity, and no evidence of HSV-2 or CMV DNA was detected in prostate tissue [72]. 
Thus, taken together, findings from these few studies do not support an association between 
HSV-2, CMV or EBV infection and risk of prostate cancer. However, it is possible that these 
studies could have potentially missed an association if only certain types of herpesvirus 
infections, such as those acquired during a critical period of prostate development, are important 
for prostate carcinogenesis. In this case, new biomarkers or new types of epidemiologic studies 
would be necessary to more fully explore the possible roles of herpesviruses in prostate 
carcinogenesis.   
Chlamydia trachomatis infection 
Another STI that has recently been investigated in relation to prostate cancer risk is 
chlamydia, a common bacterial STI. Initially, this STI was included in investigations of prostate 
cancer risk as a marker of sexual activity [63]; however, it has since been investigated in relation 
to prostate cancer in its own right because of its known ability to cause chronic, persistent 
infections, and asymptomatic and symptomatic prostate inflammation in some men [[56, 58, 89] 
and references therein]. Despite this promising rationale, most studies to date have observed 
generally null or occasionally inverse associations between a history of chlamydia and prostate 
cancer, irrespective of the study design, method of assessment (serology or self-report), type of 
C. trachomatis antibody assay used (enzyme immunoassay or micro-immunofluorescence 




A few exceptions to this statement exist. In a recent study conducted in the U.S. military, 
a suggestive positive association was observed for C. trachomatis seropositivity using serum 
specimens collected at least five years before diagnosis, but not using specimens collected closer 
to diagnosis [73]. However, as null or inverse associations were observed in other studies with 
early specimen collection [63, 89], this recent sub-group finding may have been observed by 
chance. Other possible exceptions include the suggestive positive associations observed for self-
reported history of chlamydia and prostate cancer among Asian-American and Latino men in the 
California Men’s Health Study [57]. However, these self-reported associations are difficult to 
interpret because: 1) they were based on very few exposed cases; 2) chlamydia is frequently 
asymptomatic in men and thus difficult to assess by self-report; and 3) chlamydia diagnostics 
have only been available since 1985. Therefore, self-reported infections must have been acquired 
after 1985 when participants were older and must have been either symptomatic or diagnosed in 
participants’ female partners, as men are rarely screened for chlamydia. A final exception to the 
overall generally null/inverse findings is the positive association observed for C. trachomatis 
IgA seropositivity, a marker of chronic chlamydial infection, among African-American 
participants in the PLCO study. However, no association was observed for another marker of 
chronic chlamydial infection, C. trachomatis heat shock protein 60 seropositivity [56], raising 
the possibility that these findings were observed by chance or that only certain chronic 
chlamydial infections (perhaps of a certain duration, or localized to the prostate) are associated 
with risk. Therefore, future investigations might benefit from novel biologic markers that can 
detect and distinguish between these different types of infection, and from examining men most 
likely to have had chronic infections. 
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Trichomonas vaginalis infection 
Another STI gaining recent attention is Trichomonas vaginalis infection (trichomonosis). 
T. vaginalis is a common, sexually transmitted, extracellular protozoan known to cause vaginitis 
in 20-50% of infected women and non-gonococcal urethritis and/or prostatitis in a small 
percentage of infected men [90, 91]. To our knowledge, T. vaginalis was first proposed as an 
infectious agent “of interest” for prostate carcinogenesis by Wynder and colleagues [10], 
possibly because of its known ability to cause non-gonococcal prostatitis [13], and its common 
occurrence [92]. Gardner and colleagues [93, 94] further contributed to this hypothesis when 
they observed inflammatory infiltrates and focal areas of atypical epithelial hyperplasia near T. 
vaginalis organisms in prostate tissue from infected men, leading them to propose that T. 
vaginalis might contribute to prostate carcinogenesis via an IgE-mediated anti-trichomonad 
inflammatory immune mechanism.  
Although T. vaginalis is known to cause clinical prostatitis and thus could potentially 
contribute to prostate carcinogenesis via symptomatic prostatic inflammation, it was not and still 
is not believed to be a major cause of clinical prostatitis. It may, however, be a frequent cause of 
asymptomatic prostatic inflammation. We have previously hypothesized that its frequently 
asymptomatic or non-specific presentation may allow it to persist undetected and untreated in the 
male urethra and thus possibly ascend to the prostate with greater frequency than other more 
symptomatic sexually transmitted infectious agents that are now readily detected and treated 
(e.g., N. gonorrhoeae) [95]. This hypothesis was based on the pre-antibiotic era observation of a 
10-14 day delay between onset of gonorrhea and posterior urethral involvement [96], and the 
observed dramatic decline in gonococcal prostatitis following the introduction of antibiotics, 
from which we inferred that the longer an infection is left untreated, either due to lack of 
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effective treatment or symptoms, the more likely it is to involve the prostate. We further 
hypothesized that once/if T. vaginalis reaches the prostate, its frequent lack of symptoms may 
also allow it to persist within the prostate, where it may establish a chronic focus of infection 
[95]. This hypothesis is supported by findings from early, pre-antibiotic era studies of 
trichomonosis in which investigators frequently found evidence of T. vaginalis in prostate 
specimens from asymptomatic male partners of women with trichomonal vaginitis [97-102], 
some of whom were chronically infected [101]. 
In addition to eliciting inflammation within the prostate, another possible mechanism by 
which T. vaginalis may contribute to carcinogenesis is by directly damaging or lysing prostate 
epithelial cells [95]. In in vitro studies, T. vaginalis adherence to host urogenital epithelium has 
been observed to lead to epithelial cell death and disruption of epithelial monolayer integrity 
[103-106]. Epithelial cells damaged or lysed by T. vaginalis must then be regenerated, allowing 
for possible DNA replication errors (particularly if replication occurs in the face of a potentially 
genotoxic inflammatory immune response) and hyperproliferation if secretion of growth factors 
from inflammatory immune cells becomes dysregulated [95]. T. vaginalis adhesion to urogenital 
epithelium has also been observed to upregulate expression of anti-apoptotic genes [107], which 
may potentially prevent apoptosis and allow proliferation of prostate epithelial cells damaged but 
not lysed by infection. All of these insults - inflammation, cell injury/death and inhibition of 
apoptosis - may then potentially lead to the development of PIA lesions [95]. This hypothesis is 
supported by Gardner and colleagues’ [93, 94] observation of focal areas of atypical prostatic 
epithelial hyperplasia near T. vaginalis organisms and associated inflammatory infiltrates, which, 
although not described as such, could possibly represent PIA lesions. Finally, as a further 
mechanism by which T. vaginalis may contribute to prostate carcinogenesis, T. vaginalis has 
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been observed to alter local polyamine concentrations, which have been found to be related to 
prostate cancer in some studies ([95] and references therein).  
To our knowledge, trichomonosis was first investigated in relation to prostate cancer in a 
small case-control study conducted in the late 1980s, the results of which were largely 
inconclusive because none of the participants reported a history of trichomonosis [45]. However, 
some participants likely did have a history of trichomonosis: 1) because trichomonosis tends to 
be asymptomatic in men and to be treated presumptively rather than specifically diagnosed in 
symptomatic men; and 2) because participants reported histories of other more symptomatic, 
well-known STIs, such as gonorrhea and syphilis [95]. To our knowledge, no further studies 
were conducted on trichomonosis and prostate cancer for almost two decades after this study, 
until we conducted a nested case-control study of trichomonosis and prostate cancer risk in the 
HPFS, using serology to ascertain a history of trichomonosis. In that study, we observed a 
positive association between T. vaginalis serostatus and overall prostate cancer risk (odds ratio 
(OR) =1.43, 95% CI: 1.00-2.03), and a suggestion of a more pronounced association for high-
grade disease (OR=1.76, 95% CI: 0.97-3.18) [95]. We have since conducted two additional 
investigations of trichomonosis and prostate cancer risk, one in the Prostate Cancer Prevention 
Trial (PCPT) [108], and the other in the Physician’s Health Study (PHS) [109]. While results in 
the PCPT were null, possibly due to the early stage of prostate cancer detected in that trial [108], 
results in the PHS were more consistent with our original findings. In that study, we observed a 
slight, non-significant positive association between T. vaginalis serostatus and overall prostate 
cancer risk (OR=1.23, 95% CI: 0.94-1.61), and significant, considerably more pronounced 
positive associations for risks of extraprostatic (OR=2.17, 95% CI: 1.08-4.37) and 
metastatic/fatal prostate cancer (OR=2.69, 95% CI: 1.37-5.28) [109]. Thus collectively, findings 
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from these initial studies suggest that trichomonosis may be associated with an increased risk of 
prostate cancer with the greatest potential for progression to fatal disease. However, additional 
investigations of high-grade and advanced stage prostate cancer will be necessary to rule out the 
possible role of chance, as well as additional epidemiologic and biologic studies to determine the 
validity of this possible association (e.g., studies to investigate possible confounding by other 
infectious agents). 
CONCLUSION AND FUTURE PERSPECTIVE 
Considering the literature on STIs and prostate cancer risk as a whole, particularly studies 
less susceptible to biases, a few hints exist to suggest an association between STIs and risk of 
prostate cancer. However, this possible association is not clear-cut, and may require more subtle 
investigations, both with respect to STI exposure and prostate cancer outcome, to elucidate its 
meaning. For instance, many STIs may have the potential to contribute to prostate 
carcinogenesis, as many are capable of infecting the prostate and eliciting inflammation or 
transforming prostate epithelial cells; however, their likelihood of contributing to prostate cancer 
risk may depend on additional characteristics, such as their typical duration of infection, 
likelihood of prostate infection, degree of inflammation elicited, degree of epithelial cell damage, 
and degree of other infectious agent-specific attribute(s). These characteristics may also vary in 
different settings, such as by calendar time (e.g., pre- versus current-antibiotic era), country (e.g., 
countries with access to timely STI treatment versus those without access), race, socio-economic 
status, or genetic background. Therefore, these characteristics (e.g., duration of infection) or 
markers of these characteristics (e.g., country) may need to be taken into consideration in 
interpreting previous study findings and in designing future studies. Future studies of STIs and 
prostate cancer would also benefit from the development of new biomarkers, such as those that 
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indicate chronicity of infection or prostate involvement.  
In addition to considering various aspects of STI exposure, studies of STIs and prostate 
cancer may also need to consider aspects of prostate cancer outcome, as STI(s) may not 
contribute to risk of all prostate tumors. For instance, STI(s) could possibly contribute to risk of 
prostate tumors with the potential to progress to clinically manifest or life-threatening disease, 
but not to risk of indolent prostate tumors, such as possibly observed in the case of trichomonosis 
[95, 108, 109]. Therefore, prostate cancer characteristics may also need to be taken into 
consideration in interpreting previous study findings and in designing future studies. 
Although this review has focused on infectious agents with known sexual routes of 
transmission, other genitourinary infectious agents not typically considered to be sexually 
transmitted may also be important for prostate carcinogenesis – for instance, infectious agents 
responsible for bacterial prostatitis. These organisms have been proposed to be sexually 
acquired, at least in some instances, based on their detection in the reproductive/genitourinary 
tract of both prostatitis patients and their sexual partners [110]. Therefore, these agents may be 
potential sexually transmitted infectious candidates for prostate carcinogenesis. New sexually 
transmitted infectious agents of possible relevance for prostate cancer are also likely to be 
discovered/recognized. For instance, xenotrophic murine leukemia virus-related virus (XMRV), 
a recently discovered virus in prostate tissue, has been proposed to be sexually transmitted based 
on its increased infectiousness in the presence of semen and its detection in prostate fluid, a 
component of semen [111]. This virus was initially identified in prostate tissue from men with 
prostate cancer and was found to be considerably more common in men homozygous for the 
R462Q variant allele of the ribonuclease L gene, an innate antiviral gene associated with prostate 
cancer risk in some studies, than in men carrying non-variant alleles [112]. XMRV has 
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subsequently been found to be positively associated with prostate cancer, particularly high grade 
prostate cancer, in a study of American men [113], but not in a study of German men [114], 
irrespective of R462Q variant status. Therefore, this virus may also be a potential sexually 
transmitted infectious candidate for prostate carcinogenesis.  
In summary, given the hints of an association between STI(s) and prostate cancer risk 
from the literature to date, additional investigations of known, promising STI candidates, such as 
trichomonosis, are warranted, as well as investigations of the expanding pool of newly 
discovered/recognized STI candidates. However, before beginning these studies, investigators 
should carefully consider the relevance of their measured STI exposure (i.e., how likely it is to 
capture prostate infection, chronic infections, etc.), the relevance of their prostate cancer 
outcome, and the appropriateness of their choice of study population (i.e., how likely the study 
population is to have experienced the relevant exposure or outcome of interest), in addition to 





Early hypotheses for sexually transmitted infections (STIs) and prostate cancer 
• A sexually transmitted etiology for prostate cancer was first proposed by Ravich and Ravich 
in the early 1950s to explain the higher observed prevalence of prostate cancer among mainly 
uncircumcised non-Jewish than circumcised Jewish men, similar to patterns for penile cancer 
and cervical cancer among female partners of these men. This hypothesis, together with other 
contemporary observations and hypotheses, led to a series of epidemiologic investigations on 
STIs and prostate cancer beginning in the 1970s.  
Results for early studies of STIs and prostate cancer 
• Early studies of STIs and prostate cancer (i.e., those conducted in men more likely to have 
been infected in the pre-antibiotic era) were primarily small case-control studies with 
retrospective, self-reported assessment of a narrow range of STIs, typically either any STIs, 
or gonorrhea and syphilis. In general, findings from these studies were supportive of a 
positive association between one or more of the more commonly reported STIs and prostate 
cancer. 
• Based on their study design and analysis, early studies of STIs and prostate cancer may have 
been susceptible to recall bias, interviewer bias, and confounding by hormone-associated 
libido, all of which may have possibly led to false positive associations. On the other hand, 
greater STI exposure among men who passed through adolescence and early adulthood in the 
pre-antibiotic era, and later prostate cancer presentation among men diagnosed before the 
introduction of prostate specific antigen (PSA) testing may have possibly contributed to true 
positive associations between STIs and prostate cancer. Therefore, it is difficult to determine 
the relative contributions of possible biases in study design, confounding, greater STI 
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exposure, and later prostate cancer presentation to findings from early studies of STIs and 
prostate cancer. 
Results for later studies of STIs and prostate cancer 
STIs assessed by self-report, medical record abstraction, or registry query 
• Similar to earlier case-control studies, several later case-control studies observed suggestive 
positive associations between histories of more commonly reported STIs and prostate cancer. 
These positive findings were observed in spite of several differences between earlier and 
later studies that might have served to reduce the likelihood of observing both true and false 
positive associations: less pre-antibiotic era STI exposure, earlier prostate cancer 
presentation, adjustment for correlates of libido, and lesser susceptibility to interviewer bias. 
However, one lingering concern for later case-control studies that may still have contributed 
to false positive associations is recall bias.  
• Only a few prospective studies have investigated self-reported histories of gonorrhea and 
syphilis in relation to risk of prostate cancer to avoid concerns of recall bias. In general, these 
studies have observed null associations, although positive findings among foreign-born men 
leave open the possibility of associations with specific types of infection (e.g., infections with 
a longer duration, untreated infections) less likely to have been observed in American cohort 
study populations to date. 
STIs assessed by serology and other laboratory methods 
• Since the original hypothesis on STIs and prostate cancer was first proposed, several new 
STIs have been discovered or recognized as STIs (e.g., infections by oncogenic human 
papillomavirus (HPV) types, human herpesvirus type 8 (HHV-8) and Chlamydia 
trachomatis), and new and better tests to detect histories of other known STIs have been 
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developed (e.g., herpes simplex virus type 2 (HSV-2) and Trichomonas vaginalis infections). 
Several new resources for prostate cancer research have also been created (e.g., cohort 
studies with blood collection), allowing for prospective investigations of STIs and prostate 
cancer risk, and serologic detection of STI histories, both of which serve to reduce recall 
bias.  
• In general, results for HPV, HHV-8, HSV-2, cytomegalovirus, Epstein-Barr virus, and C. 
trachomatis infection have been null. However, positive or inverse findings in some 
studies/sub-group analyses preclude firm conclusions. Therefore, more subtle investigations 
targeted at specific hypotheses (e.g., chronic prostate infections, infection during a critical 
period of prostate growth, etc.) may be necessary to elucidate possible associations between 
these STIs and prostate cancer.  
• Another STI gaining recent attention is Trichomonas vaginalis infection, a common, but less 
well-known, protozoan infection. Results from three seroepidemiologic studies conducted to 
date suggest that T. vaginalis infection may be associated with risk of prostate cancer with 
the greatest potential to progress to fatal disease. However, additional studies will be 
necessary to rule out the possible role of chance, and to investigate the validity of this 
possible association. 
Conclusion and future perspective 
• Considering the STI and prostate cancer literature as a whole, a few hints exist to suggest that 
STIs may contribute to risk of prostate cancer. However, more subtle investigations, both 
with respect to STI exposure and prostate cancer outcome, will be necessary to elucidate the 
possible role(s) of known, promising STI candidates, as well as the expanding pool of newly 
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Table 1: Early* case-control studies of sexually transmitted infections (STIs) and prostate cancer 
STIs assessed by self-report, medical record abstraction, or registry query  
Sample size Results† 
First author, year Control definition 
Cases Controls 
Exposure  
Any STIs Gonorrhea Syphilis Other STIs STIs among female partners 
Steele, 1971 [6] Hospital  BPH  39 
39 
35  Self-report 
12.8 vs 2.5% 
12.8 vs 5.7%     
Krain, 1974 [7] Hospital 221 221 Self-report 28 (12.7‡) vs 5 (2.3%‡), p=0.01     
Niijima, 1980 [22] Hospital 187   200 Medical 
record NS     




OR=1.83 (0.91-3.70)    
Any STIs: OR=2.71 (1.14-6.46) 
Any STIs: OR=2.09 (1.02-4.29) 






OR=2.3, p=0.07     




OR=0.36 (0.16-0.83)    
Any STIs: OR=1.81 (0.16-19.9) 
Any STIs: OR=1.07 (0.15-7.83) 
Fincham, 1990 
[24] Population 382 625 Self-report OR=1.02, NS    
Cervical cancer: 1 vs 0%, OR=4.94, 
NS 




344 Self-report  
26 vs 37%, NS 
10 vs 8%, NS    
Heshmat, 1973 
[11] NA§ NA§ NA§ Registry  
Coherence coefficient 
=0.990, p<0.05    
Heshmat, 1975 [9] Hospital   Self-report  25 vs 12 discordant pairs║, p<0.05    
Baker, 1981 [17] BPH 44 90 Self-report  32 vs 22% 5 vs 8% 
“Recurrent genital 
sores”: 5 vs 0% 
Pediculus pubis: 
 5 vs 7% 
 
Mishina, 1985 [23] Population 100 100 Self-report  OR=1.45, χ2=0.59 OR=1.50, χ2=0.10  
Gonorrhea: OR=1.33, χ2=0 
Syphilis: OR=5.00, χ2=0.50 
Colpitis/vaginitis: OR=1.00, χ2=1.00 
Cervical cancer: OR=5.00, χ2=0.50 








OR=5.5, p<0.05   
Feminella, 1975 
[27] BPH 101 101 
Medical 
record     
Cervical cancer:** 3 vs 0%, χ2=3.04, 
NS relative to controls 






Widowers who died 
of any other cause†† 
Married men with 







Registry     
Cervical cancer:  
OR=1.55 (0.65-3.86) 
Cervical cancer:  
OR=0.35 (0.12-0.98) 
Jackson, 1981 [26] Hospital 205 205 Self-report    
Urethritis: reported 
“more frequently 
by [cases] than 
controls” OR<2, 
p<0.05 
Genital infection: reported by “more 
[cases] than controls”, “definite, 
although statistically not significant” 
Genital cancer: NS 
STIs assessed by serology or other laboratory methods 
Sample size Results† 
First author, year Control definition 
Cases Controls 
Exposure  
HSV-2 CMV EBV 
Herbert, 1976 [16] BPH 28 20 Antibody 71 vs 66%, NS   









95, 95, 80 vs 70, 53, 79%§§ 
95, 95, 80 vs 78, 89, 84%§§ 
95, 95, 80 vs 61, 78, 55%§§ 
 
Baker, 1981 [17] BPH 50 159 Antigen Antibody 
2 (4.0‡) vs 4 (2.5%‡) 
68 vs 51%, p<0.05   
Boldogh, 1983 [20] Normal BPH 10 
13 
9 
DNA, RNA or 
antigen 
2 (20.0‡) vs 1 (7.7%‡) 
2 (20.0‡) vs 0 (0.0%‡) 
4 (40.0‡) vs 2 (15.4%‡) 
4 (40.0‡) vs 3 (33.3%‡)  
Haid, 1984 [18] BPH 27 33 Antigen 25.5 vs 24.2%, p>0.8   









BPH = benign prostatic hyperplasia; CMV = cytomegalovirus; EBV = Epstein-Barr virus; HSV-2 = herpes simplex virus type 2; OR = odds ratio; NA = not applicable; 
NS = not statistically significant. 
*  Early was defined as a mean, median or midpoint age (depending on how the study population was described) of ≥25 years of age as of 1937, the approximate year 
when sulphonamide antibiotics were first introduced for treatment of gonorrhea. 
†  Raw results are provided exactly as described in each manuscript unless otherwise specified. These results are interpreted in the text. In the case in which two 
proportions or numbers are presented, the first refers to cases and the second to controls unless otherwise specified. 
‡ Derived from data provided in the manuscript. 
§ Ecologic study. 
║ The first number of pairs refers to discordant pairs in which the case was exposed and the control was unexposed, and the second number of pairs refers to 
discordant pairs in which the case was unexposed and the control was exposed. 
** Results for cervicitis, vaginitis and syphilis are not presented because the timing of these diagnoses with respect to their husbands’ prostate cancer or BPH 
diagnosis is unclear. 
†† Cases were widowers who died of prostate cancer. 
39 
 
‡‡ Cases were married men with prostate cancer. 
§§ Three different serologic assays were used. 
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Table 2:  Later* case-control studies of sexually transmitted infections (STIs) assessed primarily by self-report and prostate cancer 
Sample size  Results† 
First author, year Control definition 
Cases Controls Exposure Any STIs Gonorrhea Syphilis Other STIs STIs among female partners 
Hayes, 1992 [46] Hospital 100 113 Self-report NS (low prevalence)     
Ewings, 1996 [47] Hospital and BPH 159 325 Self-report OR=2.06 (0.38-11.22)    Cervical cancer: OR=0.56 (0.06-2.98) 
Lightfoot, 2004 [38] Population 760 1,632 Self-report OR=2.12 (1.27-3.53)     
Fernandez, 2004 
[39] Hospital 273 254 Self-report OR=1.7 (1.1-2.5)     
Checkoway, 1987 
[45] BPH 40 64 Self-report  10.0 vs 7.8% 5.0 vs 4.7% 
Genital herpes: 0.0 vs 
0.0%‡ 
Other STI: 0.0 vs 0.0% 
 
Honda, 1988 [44] Population 216 216 Self-report  OR=1.4 (0.8-2.6) OR=6.0 (0.7-276.0)   
Ilic, 1996 [40] Hospital 101 202 Self-report  4.0 vs 0.0%, p>0.10§    
Hsieh, 1999 [36] Hospital 320 246 Self-report  χ for contrast or trend=0.73, p=0.47  
Other STI: χ for 
contrast or trend= 
-0.31, p=0.76 
 





















OR=0.8 (0.2-3.5)║  
  
Rosenblatt, 2001 






























Could not be estimated 
Genital herpes:  Could 
not be estimated 
Chancroid: OR=0.2 
(0.02-1.9) 
Other STIs: OR=1.8 
(0.3-9.6) 







Other STIs: OR=0.7 
(0.1-3.9) 
Pelucchi, 2006 [48] 
and La Vecchia, 
1993 [49] 
Hospital 280 689 Self-report  OR=0.64 (0.20-2.03) OR=1.75 (0.10-31.44) 
Genital herpes: NS 
(low number exposed) 
Genital warts: Could 
not be estimated 
 
Sarma, 2006 [43] Population 129 703 Self-report  OR=1.78 (1.13-2.79) OR=1.54 (0.55-4.34) 
Herpes: OR=0.89 
(0.11-7.70) 




Newell, 1989 [50] Other cancer 110 220     Genital warts: NS  
BPH = benign prostatic hyperplasia; OR = odds ratio; NS = not statistically significant. 
*  Later was defined as a mean, median or midpoint age (depending on how the study population was described) of <25 years of age as of 1937, the approximate year 
when sulphonamide antibiotics were first introduced for treatment of gonorrhea. 
†  Raw results are provided exactly as described in each manuscript unless otherwise specified. These results are interpreted in the text. In the case in which two 
proportions or numbers are presented, the first refers to cases and the second to controls unless otherwise specified. 
‡ Results for Trichomonas vaginalis infection are described later in the text in the section on T. vaginalis infection.   
§ Recalculated using Fisher’s exact test as p=0.01. 
║ Serologic testing was performed on a subset of the study population: 125 Black cases, 131 Black controls, 146 White cases and 155 White controls. 
** Results for Chlamydia trachomatis infection are described later in Table 5.
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Table 3:  Prospective studies of sexually transmitted infections (STIs) assessed by self-report, medical record abstraction, or registry query and prostate cancer 
Results* 
First author, year Study design Sample size Exposure  
Gonorrhea Syphilis Other STIs 
Hiatt, 1994 [51] Nested case-control 238 cases, 238 controls Medical record OR=1.5 (0.5-4.2)   
Michalek, 1994 [52] Cohort Approximately 10,262 exposed† Registry  SIR=58 (37-86)  
Sutcliffe, 2006 [55] Cohort 32,932 Self-report RR=1.04 (0.79-1.36) RR=1.06 (0.44-2.59)  




Black: 103 cases, 368 controls  
White: 765 cases, 915 controls 









































Genital herpes:  RR=0.91 (0.57-1.46)  
Genital warts:  RR=0.55 (0.28-1.07)§ 
Genital herpes:  RR=0.78 (0.58-1.06)  
Genital warts:  RR=0.93 (0.70-1.25)§ 
Genital herpes:  RR=1.20 (0.38-3.81)  
Genital warts:  RR=Could not be estimated§ 
Genital herpes:  RR=1.16 (0.63-2.13) 
Genital warts:  RR=0.44 (0.16-1.19)§ 
Genital herpes:  RR=0.75 (0.10-5.54) 
Genital warts:  RR=0.58 (0.08-4.25)§ 
OR = odds ratio; RR = relative risk; SIR = standardized incidence ratio. 
*  Raw results are provided exactly as described in each manuscript unless otherwise specified. These results are interpreted in the text. 
†  Derived from data provided in the manuscript. 
‡ Provided by authors. 
§ Results for Chlamydia trachomatis infection are described later in Table 5. 
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Table 4:  Seroepidemiologic studies of human papillomavirus (HPV) infection and prostate cancer 
Result* 
First author, year Study design Sample size 
HPV-16 HPV-18 Other HPV types 
Strickler, 1998 [115] Case-control 63 cases, 144 BPH controls 
p=0.54 for geometric mean 
comparison 
1.6 vs 4.9%, p=0.44 
 
HPV-11: p=0.64 for geometric mean 
comparison 
Strickler, 1998 [116] Case-control 47 cases, 48 endocrine disorder 
controls 6 vs 4%  
 
Dillner, 1998 [63] Nested case-control 165 cases, 290 controls OR=2.58 (0.77-8.56) OR=2.88 (1.27-6.56) HPV-33: OR=0.66 (0.26-1.66)† HPV-11: OR=0.61 (0.27-1.39)† 
Hisada, 2000 [64] Nested case-control 48 cases, 63 controls OR=2.7 (0.9-7.9)   
Rosenblatt, 2003 
[66] Case-control 642 cases, 570 population controls OR=1.06 (0.71-1.57) OR=1.36 (0.69-2.69) 
 
Adami, 2003 [67] Case-control 238 cases, 210 population controls OR=0.7 (0.4-1.3) OR=0.9 (0.5-1.9) HPV-33: OR=1.6 (1.0-2.7) 
Korodi, 2005 [70] Nested case-control 
Finland: 136 cases, 498 controls 
Sweden: 87 cases, 346 controls 
Norway: 577 cases, 1,752 controls 









HPV-33: OR=1.04 (0.45-2.44) 
HPV-33: OR=0.89 (0.36-2.22) 
HPV-33: OR=1.00 (0.69-1.47) 
HPV-33: OR=0.99 (0.72-1.38) 
Sitas, 2007 [71] Case-control 205 cases, 673 other cancer and 
cardiovascular disease controls 
Medium:‡ OR=1.33 (0.87-2.04) 
High:‡ OR=1.22 (0.77-1.93) 
  
Sutcliffe, 2007 [58] Nested case-control 691 cases, 691 controls OR=0.83 (0.57-1.23) OR=1.04 (0.66-1.64) HPV-33: OR=1.14 (0.76-1.72) 






Dennis, 2009 [73] Nested case-control 267 cases, 267 controls 
Mean 10 mo§,  HPV-16 or -18:  OR=0.92 (0.59-1.45), HPV-16,-18,-6 or -11: OR=1.07 (0.75-1.52) 
Mean 94 mo§,  HPV-16 or -18:  OR=1.13 (0.73-1.75), HPV-16,-18,-6 or -11: OR=0.98 (0.69-1.40) 
>60 mo§,  HPV-16 or -18: OR=1.20 (0.74-1.95), HPV-16,-18,-6 or -11: OR=1.00 (0.67-1.50) 
Sutcliffe, 2010 [74] Nested case-control 616 cases, 616 controls 
Weak:‡ OR=0.94 (0.53-1.64) 
 
Strong:‡ OR=1.07 (0.77-1.48) 
Weak:‡ OR=0.75 (0.27-2.04) 
 
Strong:‡ OR=0.87 (0.47-1.63) 
HPV-31, weak:‡  
OR=0.76 (0.45-1.28) 
HPV-31, strong:‡  
OR=1.15 (0.80-1.64) 
BPH = benign prostatic hyperplasia; OR = odds ratio. 
*  Raw results are provided exactly as described in each manuscript unless otherwise specified. These results are interpreted in the text. In the case in which two 
proportions or numbers are presented, the first refers to cases and the second to controls unless otherwise specified. 
† Crude OR. Other ORs presented for Diller, 1998 [63] are adjusted.  
‡ Seropositivity. 
§ Collection of serum before prostate cancer diagnosis.
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Table 5:  Later* case-control studies of other sexually transmitted infections (STIs) typically assessed by serology or other laboratory methods and prostate cancer 
Result† 
First author, year Study design Sample size Exposure  
HHV-8 HSV-2, CMV or EBV C. trachomatis 
Monini, 1996 [81] Case-control 8 cases, 8 BPH controls DNA 25 vs 63%   
Tasaka, 1997 [83] Case-control 32 cases, 20 BPH controls DNA No DNA detected   
Lebbe, 1997 [84] Case-control 6 cases, 13 BPH controls, 3 normal 
controls DNA No DNA detected 
  
Sitas, 1999 [82] 
Cross-sectional 
survey of cancer 
patients 
3,293 patients (202 prostate cancer, 
3,091 other cancer)    Antibody NS 
  
Hoffman, 2004 [85] Case-control 
Caribbean: 
138 Tobago cases, 140 Tobago controls 
174 Trinidad controls 
United States:  
100 cases, 99 other cancer controls 









Korodi, 2005 [86] Nested case-control 163 cases, 288 controls Antibody OR=0.74 (0.19-2.88) HSV-2: OR=0.93 (0.44-1.96)  
Italy: 
10 cases, 34 BPH controls 
Lytic IFA: OR=1.08 (0.27-4.33) 
K8.1 ELISA: OR=0.813 (0.17-4.21) 
ORF73 ELISA: OR=0.60 (0.12-3.03) 
United States:  
Black: 41 cases, 98 BPH controls 
Lytic IFA: OR=0.88 (0.35-2.24) 
K8.1 ELISA: OR=0.328 (0.10-1.11) 
ORF73 ELISA: OR=0.43 (0.16-1.18) 
Black: 95 cases, 75 population controls 
Lytic IFA: OR=0.56 (0.28-1.14) 
K8.1 ELISA: OR=0.52 (0.10-2.66) 
ORF73 ELISA: OR=0.62 (0.17-2.20) 
Jenkins, 2007 [87] Case-control 
White: 104 cases, 80 population controls 
Antibody 
Lytic IFA: OR=0.71 (0.36-1.43) 
K8.1 ELISA: OR=0.76 (0.17-3.40) 
ORF73 ELISA: OR=0.77 (0.13-4.44) 
  
Sutcliffe, 2007 [58] Nested case-control 691 cases, 691 controls Antibody OR=0.70 (0.52-0.95)  OR=1.13 (0.65-1.96) 
Huang, 2008 [56] Nested case-control 
Black: 103 cases, 368 controls 
 





HSV-2: OR=1.3 (0.8-2.0) 
CMV: OR=0.9 (0.4-1.7) 
HSV-2: OR=0.9 (0.7-1.3) 
CMV: OR=1.1 (0.9-1.3) 
IgG: OR=1.1 (0.7-1.7) 
IgA: OR=2.1 (1.2-3.6) 
IgG: OR=1.2 (0.9-1.6) 
IgA: OR=0.7 (0.4-1.1) 
Berrington de 
Gonzalez, 2006 [88] Case-control 
66 cases, 95 other cancer controls, 101 




Bergh, 2007 [72] Nested case-control 159 cases, 159 controls DNA  HSV-2: No DNA detected  
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CMV: No DNA detected 
EBV: 9.4 vs 8.8% 
Dennis, 2009 [73] Nested case-control 267 cases, 267 controls Antibody 
 HSV-2, mean 10 mo‡:  
OR=1.17 (0.79-1.73)  
HSV-2, mean 94 mo‡:  
OR=1.60 (1.05-2.44) 
HSV-2, >60 mo‡:  
OR=2.04 (1.26-3.29) 
Mean 10 mo‡:  
OR=1.07 (0.64-1.81) 
Mean 94 mo‡:  
OR=1.35 (0.79-2.31) 
>60 mo‡:  
OR=1.80 (0.96-3.38) 
Dillner, 1998 [63] Nested case-control 165 cases, 290 controls Antibody   OR=1.04 (0.54-2.00) 
Rosenblatt, 2001 
[42] Case-control 753 cases, 703 population controls Self-report 
  OR=0.43 (0.12-1.48) 
Anttila, 2005 [89] Nested case-control 
Finland: 138 cases, 497 controls 
Sweden: 86 cases, 341 controls 
Norway: 514 cases, 1,433 controls 
Total: 738 cases, 2,271 controls 
Antibody 











  RR=1.00 (0.62-1.63) 
RR=0.88 (0.59-1.32) 
RR=5.55 (1.70 -18.09) 
RR=1.82 (0.80-4.15) 
RR=1.39 (0.19-0.18) 
BPH = benign prostatic hyperplasia; CMV = cytomegalovirus; EBV = Epstein-Barr virus; ELISA = enzyme-linked immunosorbent assay; HSV-2 = herpes simplex virus type 
2; HHV-8 = human herpesvirus type 8; OR = odds ratio; IFA = immunofluorescence assay; NS = not statistically significant; RR = relative risk. 
*  Later was defined as a mean, median or midpoint age (depending on how the study population was described) of <25 years of age as of 1937, the approximate year when 
sulphonamide antibiotics were first introduced for treatment of gonorrhea. 
†  Raw results are provided exactly as described in each manuscript unless otherwise specified. These results are interpreted in the text. In the case in which two proportions 
or numbers are presented, the first refers to cases and the second to controls unless otherwise specified.  
‡ Collection of serum before prostate cancer diagnosis. 
 
